Frequently Asked Questions

When Drug Enforcement Administration investigators document diversion, inventory gaps, or paperwork lapses, the inspection report is only the opening salvo: revocation actions, six-figure fines, False Claims Act lawsuits, federal health-care program exclusion, state license loss, payer claw-backs, and even loan defaults can cascade within weeks, threatening a pharmacy’s very existence.

The chain reaction usually starts with an Order to Show Cause or, in urgent cases, an Immediate Suspension Order that halts all controlled-substance activity on the spot. Agents often urge owners to sign DEA Form 104 and “voluntarily” surrender the registration, a decision that industry counsel warn is almost impossible to undo. Even a lesser Letter of Admonition becomes public record and signals every other regulator that trouble is afoot.

Next come civil monetary penalties.  Under the 2025 inflation adjustment, record-keeping errors cost up to $18 759 each and each invalid prescription up to $80 850, so a routine inventory gap can mushroom into mid-six-figure liability; Community Health Pharmacy in New Haven paid $192 000 on June 1 2025 for just such lapses.

Because the same unlawful prescriptions are typically billed to Medicare or Medicaid, DOJ lawyers now tack on False Claims Act counts: the April 21 2025 Walgreens settlement pairs CSA and FCA theories for up to $350 million and embeds a multi-year compliance monitorship.

An adverse DEA finding also unlocks HHS-OIG’s discretionary exclusion power; once excluded, a provider cannot bill any federal program, and DEA regulations treat that loss of “public interest” as an independent ground to revoke the pharmacy’s DEA registration.

Private payers and pharmacy benefit managers (PBM’s) move just as quickly.  OptumRx’s 2025 provider manual authorizes immediate network suspension when a pharmacy’s license or DEA authority is “in jeopardy,” while contract fine print lets PBMs pursue recoupment for every claim tied to a questioned prescription. Losing those contracts can erase 70-plus percent of gross revenue overnight and spook wholesalers, banks, and insurers that monitor public DEA dockets for risk signals.

Finally, inspection files often feed criminal probes: lying to agents, back-dating records, or obstructing an audit can trigger felony charges even when diversion counts never materialize, as recent civil-penalty complaints in Houston demonstrate.  Add the cost of outside consultants and the mandatory system upgrades that accompany settlement monitorships, and the true price of a failed DEA inspection can dwarf the original fine.

Frequently Asked Questions

Q: Can I continue dispensing while I fight an Order to Show Cause?

A: Yes, but not if the DEA also issues an Immediate Suspension Order; an ISO shuts down controlled-substance activity until the case is resolved.

Q: Should I ever sign DEA Form 104?

A: Only after counsel reviews the inspection findings; voluntary surrender is faster than revocation but far harder to reverse.

Q: How do civil fines get so high so fast?

A: Each missing line-item, Form 222 error, or invalid prescription is a separate violation—currently $18 759 or $80 850 apiece—so ten mistakes can exceed $500 000.

Q: What other agencies will find out about a bad inspection?

A: HHS-OIG (exclusion), state boards (license action), the NPDB (permanent record), PBMs (network status), and sometimes the U.S. Attorney’s Office (FCA claims).

Q: How can I limit the damage?

A: Engage experienced counsel before agents leave the premises, conduct an immediate inventory reconciliation, and prepare comprehensive corrective-action documentation for every stakeholder—DEA, state board, PBMs, and payers alike.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

Standing Up for Pharmacies: How HLA Fought and Reversed Optum’s Termination of a New York Pharmacy

 In a recent victory, our attorneys at Health Law Alliance achieved a full reversal of Optum’s termination of a New York pharmacy. Read about how HLA fought tirelessly to rebut Optum’s allegations and how Health Law Alliance can defend your pharmacy from an unjust termination.

Read More >>

DME Supplier Defense Attorneys' Guide to the Different Types of Government Audits

For DME suppliers, a notice from CMS can be daunting, especially when you're trying to figure out the difference between a TPE, SMRC, and UPIC. Each of these audit contractors has a different mission, scope, and level of risk for your business. Our latest blog post breaks down the "alphabet soup" of CMS audits, explaining what each entity does, what they look for, and how you should respond when they contact you. Protect your business by understanding who is on the other side of the audit.

Read More >>

Building an Audit-Proof Documentation System for Your DME Supplier Business

In a CMS audit, your documentation is your only defense. A missing signature or an incomplete progress note can lead to a costly overpayment demand. Is your record-keeping system truly protecting you? This article provides a blueprint for creating an audit-proof documentation system. We cover everything from intake checklists to monthly note requirements for wound care supplies, helping you ensure every claim is fully supported and ready for scrutiny.

Read More >>

Health Law Alliance Successfully Sues the DEA and its Administrator, Terrance Cole, in Federal Court to Lift Immediate Suspension Order

Health Law Alliance is proud to announce a major victory in federal court, where it successfully secured the immediate lifting of a DEA suspension against a Florida community pharmacy, restoring its full authority to dispense controlled substances. This outcome ensures uninterrupted patient care and underscores the firm’s commitment to protecting healthcare providers from government overreach.

Read More >>